Bimekizumab In Ankylosing Spondylitis - Dr. Rachel Tate Save
Dr. Rachel Tate from EULAR2020 Virtual Conference
Transcription
Hi, RheumNow. It's Doctor. Rachel Tate again presenting for EULAR twenty twenty and the eCongress from beautiful West Palm Beach, Florida where it is currently rainy. I just wanted to talk to you about one particular study today that I found to be really important. This is by Doctor.
Vanderhage and her colleagues, who presented the patient reported outcomes from the B Agile trial for AS. Now as you know this trial looked at bimekizumab which neutralizes IL-17A and 17F, and it looked at three hundred AS patients who had active disease despite treatment with nonsteroidal anti inflammatories. Now these patients were randomized into five groups. There was one placebo group and then four different doses of bimekizumab, and then after week twelve which was a primary endpoint, they actually re randomized the patients who were still within the trial into either bimekizumab one hundred and sixty milligrams every four weeks or three twenty milligrams every four weeks for the remaining thirty six weeks of this particular forty eight week trial. So the week 12 and week fourteen data, and again, this is patient reported outcomes, actually showed that the patients on bemecizumab overall felt improvement with the drug and, versus placebo, of course, and there was no quantifiable difference for the patients in between either the one hundred and sixty or three twenty milligram dosing.
Of course, no new safety signals otherwise we would have talked about that as well, but I think it's really important when we're talking about trials to remember that patient reported outcomes are really important to our patients. Right? That's what they're kind of going home for. They're making sure that they're having a good experience just as well as we're able to objectively qualify that when looking at trials. So, I think we'll learn a little bit more about this as we come down the pipeline.
I'm hoping it's another option for treatment for patients, and we'll see where it ends up. But this is pretty good data, it sounds like a good start. So I hope you are doing well. I hope your families are safe during this pandemic. And, again, this is doctor Rachel Tate coming to you from West Palm Beach, Florida presenting at ULAR twenty twenty, the e congress, which is currently out of Germany and now electronic.
So check us out on roomnow.com for more information, and please continue to check your Twitter feeds.
Vanderhage and her colleagues, who presented the patient reported outcomes from the B Agile trial for AS. Now as you know this trial looked at bimekizumab which neutralizes IL-17A and 17F, and it looked at three hundred AS patients who had active disease despite treatment with nonsteroidal anti inflammatories. Now these patients were randomized into five groups. There was one placebo group and then four different doses of bimekizumab, and then after week twelve which was a primary endpoint, they actually re randomized the patients who were still within the trial into either bimekizumab one hundred and sixty milligrams every four weeks or three twenty milligrams every four weeks for the remaining thirty six weeks of this particular forty eight week trial. So the week 12 and week fourteen data, and again, this is patient reported outcomes, actually showed that the patients on bemecizumab overall felt improvement with the drug and, versus placebo, of course, and there was no quantifiable difference for the patients in between either the one hundred and sixty or three twenty milligram dosing.
Of course, no new safety signals otherwise we would have talked about that as well, but I think it's really important when we're talking about trials to remember that patient reported outcomes are really important to our patients. Right? That's what they're kind of going home for. They're making sure that they're having a good experience just as well as we're able to objectively qualify that when looking at trials. So, I think we'll learn a little bit more about this as we come down the pipeline.
I'm hoping it's another option for treatment for patients, and we'll see where it ends up. But this is pretty good data, it sounds like a good start. So I hope you are doing well. I hope your families are safe during this pandemic. And, again, this is doctor Rachel Tate coming to you from West Palm Beach, Florida presenting at ULAR twenty twenty, the e congress, which is currently out of Germany and now electronic.
So check us out on roomnow.com for more information, and please continue to check your Twitter feeds.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.